Distaclor/cefaclor 500mg capsules.

Distaclor/cefaclor 125mg/5ml.

Distaclor/cefaclor 250mg/5ml.

Each capsule contains, as the active ingredient, cefaclor monohydrate PhEur, equivalent to 500mg of cefaclor base.

Each 5ml of reconstituted 125mg/5ml suspension contains, as the active ingredient, cefaclor monohydrate PhEur, equivalent to 125mg of cefaclor base.

Each 5ml of reconstituted 250mg/5ml suspension contains, as the active ingredient, cefaclor monohydrate PhEur, equivalent to 250mg of cefaclor base.

500mg capsule, size 0, with opaque purple cap and opaque grey body

Granules for oral suspension.

Distaclor is indicated for the treatment of the following infections due to susceptible microorganisms:

Respiratory tract infections, including pneumonia, bronchitis, exacerbations of chronic bronchitis, pharyngitis and tonsillitis, and as part of the management of sinusitis

Otitis media

Skin and soft tissue infections

Urinary tract infections, including pyelonephritis and cystitis

Distaclor has been found to be effective in both acute and chronic urinary tract infections.

Cefaclor is generally effective in the eradication of streptococci from the nasopharynx, however, data establishing efficacy in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available.

Distaclor is administered orally.

Adults: The usual adult dosage is 250mg every eight hours. For more severe infections or those caused by less susceptible organisms, doses may be doubled. Doses of 4g per day have been administered safely to normal subjects for 28 days, but the total daily dosage should not exceed this amount.

Distaclor may be administered in the presence of impaired renal function. Under such conditions, dosage is usually unchanged (see 'Special warnings and special precautions for use').

Patients undergoing haemodialysis: Haemodialysis shortens serum halflife by 2530%. In patients undergoing regular haemodialysis, a loading dose of 250mg1g administered prior to dialysis and a therapeutic dose of 250500mg every six to eight hours maintained during interdialytic periods is recommended.

The elderly: As for adults.

Children: The usual recommended daily dosage for children is 20mg/kg/day in divided doses, every eight hours, as indicated. For bronchitis and pneumonia, the dosage is 20mg/kg/day in divided doses, administered 3 times daily. For otitis media and pharyngitis, the total daily dosage may be divided and administered every 12 hours. Safety and efficacy have not been established for use in infants aged less than one month.

Distaclor Suspension

In more serious infections, otitis media, sinusitis and infections caused by less susceptible organisms, 40mg/kg/day in divided doses is recommended, up to a daily maximum of 1g.

In the treatment of betahaemolytic streptococcal infections, therapy should be continued for at least 10 days.

Hypersensitivity to cephalosporins.

Warnings

Before instituting therapy with cefaclor, every effort should be made to determine whether the patient has had previous hypersensitivity reactions to cefaclor, cephalosporins, penicillins or other drugs. Cefaclor should be given cautiously to penicillinsensitive patients, because crosshypersensitivity, including anaphylaxis, among betalactam antibiotics has been clearly documented.

If an allergic reaction to cefaclor occurs, the drug should be discontinued and the patient treated with the appropriate agents.

Pseudomembranous colitis has been reported with virtually all broadspectrum antibiotics, including macrolides, semisynthetic penicillins and cephalosporins. It is important, therefore, to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Such colitis may range in severity from mild to lifethreatening. Mild cases usually respond to drug discontinuance alone. In moderate to severe cases, appropriate measures should be taken.

Precautions

Cefaclor should be administered with caution in the presence of markedly impaired renal function. Since the halflife of cefaclor in anuric patients is 2.3 to 2.8 hours (compared to 0.60.9 hours in normal subjects), dosage adjustments for patients with moderate or severe renal impairment are not usually required. Clinical experience with cefaclor under such conditions is limited; therefore, careful clinical observation and laboratory studies should be made.

Broadspectrum antibiotics should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.

Prolonged use of cefaclor may result in the overgrowth of nonsusceptible organisms. If superinfection occurs during therapy, appropriate measures should be taken.

Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies or in transfusion crossmatching procedures, when antiglobulin tests are performed on the minor side, or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.

A falsepositive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets.

There have been rare reports of increased prothrombin time, with or without clinical bleeding, in patients receiving cefaclor and warfarin concomitantly. It is recommended that in such patients, regular monitoring of prothrombin time should be considered, with adjustment of dosage if necessary.

The renal excretion of cefaclor is inhibited by probenecid.

Usage in pregnancy: Animal studies have shown no evidence of impaired fertility or teratogenicity. However, since there are no adequate or wellcontrolled studies in pregnant women, caution should be exercised when prescribing for the pregnant patient.

Usage in nursing mothers: Small amounts of cefaclor have been detected in breast milk following administration of single 500mg doses. Average levels of about 0.2 micrograms/ml or less were detected up to 5 hours later. Trace amounts were detected at one hour. As the effect on nursing infants is not known, caution should be exercised when cefaclor is administered to a nursing woman.

Not applicable.

Gastrointestinal: The most frequent sideeffect has been diarrhoea. It is rarely severe enough to warrant cessation of therapy. Colitis, including rare instances of pseudomembranous colitis, has been reported. Nausea and vomiting have also occurred.

Hypersensitivity: Allergic reactions such as morbilliform eruptions, pruritus and urticaria have been observed. These reactions usually subside upon discontinuation of therapy. Serum sicknesslike reactions (erythema multiforme minor, rashes or other skin manifestations accompanied by arthritis/arthralgia, with or without fever) have been reported. Lymphadenopathy and proteinuria are infrequent; there are no circulating immune complexes and no evidence of sequelae. Occasionally, solitary symptoms may occur, but do not represent a serum sicknesslike reaction. Serum sicknesslike reactions are apparently due to hypersensitivity and have usually occurred during or following a second (or subsequent) course of therapy with cefaclor. Such reactions have been reported more frequently in children than in adults. Signs and symptoms usually occur a few days after initiation of therapy and usually subside within a few days of cessation of therapy. Antihistamines and corticosteroids appear to enhance resolution of the syndrome. No serious sequelae have been reported.

There are rare reports of erythema multiforme major (StevensJohnson syndrome), toxic epidermal necrolysis, and anaphylaxis. Anaphylaxis may be more common in patients with a history of penicillin allergy. Anaphylactoid events may present as solitary symptoms, including angioedema, asthenia, oedema (including face and limbs), dyspnoea, paraesthesias, syncope, or vasodilatation.

Rarely, hypersensitivity symptoms may persist for several months.

Haematological: Eosinophilia, positive Coombs' tests and, rarely, thrombocytopenia. Transient lymphocytosis, leucopenia and, rarely, haemolytic anaemia, aplastic anaemia, agranulocytosis and reversible neutropenia of possible clinical significance. See 'Interactions with other medicaments and other forms of interaction'.

Hepatic: Transient hepatitis and cholestatic jaundice have been reported rarely, slight elevations in AST, ALT or alkaline phosphatase values.

Renal: Reversible interstitial nephritis has occurred rarely, also slight elevations in blood urea or serum creatinine or abnormal urinalysis.

Central nervous system: Reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations and somnolence have been reported rarely.

Miscellaneous: Genital pruritus, vaginitis and vaginal moniliasis.

Symptoms of nausea, vomiting, epigastric distress and diarrhoea would be anticipated.

Treatment: Unless 5 times the normal total daily dose has been ingested, gastrointestinal decontamination will not be necessary.

General management may consist of supportive therapy.

Cefaclor is active against the following organisms in vitro:

Alpha and betahaemolytic streptococci

Staphylococci; including coagulasepositive, coagulasenegative and penicillinaseproducing strains

Streptococcus pneumoniae

Streptococcus pyogenes (group A betahaemolytic streptococci)

Branhamella catarrhalis

Escherichia coli

Proteus mirabilis

Klebsiella species

Haemophilus influenzae, including ampicillinresistant strains.

Cefaclor has no activity against Pseudomonas species or Acinetobacter species. Methicillinresistant staphylococci and most strains of enterococci (eg, Str. faecalis) are resistant to cefaclor. Cefaclor is not active against most strains of Enterobacter spp, Serratia spp, Morganella morganii, Proteus vulgaris and Providencia rettgeri.

Cefaclor is well absorbed after oral administration to fasting subjects. Total absorption is the same whether the drug is given with or without food; however, when it is taken with food, the peak concentration achieved is 5075% of that observed when the drug is administered to fasting subjects and generally appears from ¾ to one hour later. Following administration of 250mg, 500mg and 1g doses to fasting subjects, average peak serum levels of approximately 7, 13 and 23 mg/l, respectively, were obtained within 30–60 minutes. Approximately 60–85% of the drug is excreted unchanged in the urine within eight hours, the greater portion being excreted within the first two hours. During the eight hour period, peak urine concentrations following the 250mg, 500mg and 1g doses were approximately 600, 900 and 1,900 mg/l, respectively. The serum halflife in normal subjects is 0.6–0.9 hours. In patients with reduced renal function, the serum halflife of cefaclor is slightly prolonged. In those with complete absence of renal function, the plasma halflife of the intact molecule is 2.3–2.8 hours. Excretion pathways in patients with markedly impaired renal function have not been determined. Haemodialysis shortens the halflife by 2530%.

There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

None Known.

Capsule: 3 years.

Suspensions: 24 months.

Capsule: Store below 25°C. Keep containers tightly closed and protect from light.

Suspensions: Store at room temperature (1525°C). Keep containers tightly closed and protect from light. After reconstitution, the suspension should be stored in a refrigerator (28°C) and be used within 14 days.

Capsule: Highdensity polyethylene bottles with screw caps containing 50 capsules.

Suspensions: The product is filled into highdensity polyethylene bottles with screw caps containing 100ml of cefaclor.

Capsule: None.

Suspensions: When dilution is unavoidable, syrup BP should be used after the suspension has been prepared according to the manufacturer's instruction.

Flynn Pharma Limited

Alton House

4 Herbert Street

Dublin

Ireland

500 mg capsule: PL 13621/0008

125mg/5ml suspension: PL 13621/0009

250mg/5ml suspension: PL 13621/0010

Date of first authorisation: 21 August 1978

Date of last renewal of authorisation: Capsule: 4 October 1994

Suspensions: 29 July 1994

Capsule: Nov 2005

Suspensions: April 1999